Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 5
1967 8
1968 2
1969 3
1970 3
1971 8
1972 10
1973 10
1974 14
1975 20
1976 19
1977 18
1978 12
1979 9
1980 12
1981 11
1982 11
1983 14
1984 20
1985 13
1986 21
1987 16
1988 21
1989 32
1990 14
1991 30
1992 21
1993 26
1994 22
1995 24
1996 24
1997 39
1998 33
1999 35
2000 23
2001 33
2002 36
2003 48
2004 73
2005 66
2006 84
2007 89
2008 85
2009 70
2010 71
2011 86
2012 81
2013 86
2014 77
2015 58
2016 70
2017 75
2018 58
2019 46
2020 38
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

1,730 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD.
Barragán E, Breuer D, Döpfner M. Barragán E, et al. J Atten Disord. 2017 Mar;21(5):433-441. doi: 10.1177/1087054713518239. Epub 2016 Jul 28. J Atten Disord. 2017. PMID: 24464327 Clinical Trial.
OBJECTIVE: To compare efficacy of Omega-3/6 fatty acids (Equazen eye q) with methylphenidate (MPH) and combined MPH + Omega-3/6 in children with ADHD. ...ADHD symptoms were assessed using the ADHD Rating Scale and Clinical Global Impressions-Severity (CGI-S) scale. …
OBJECTIVE: To compare efficacy of Omega-3/6 fatty acids (Equazen eye q) with methylphenidate (MPH) and combined MPH + Omega-3/6 in ch …
Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II).
Asherson P, Johansson L, Holland R, Fahy T, Forester A, Howitt S, Lawrie S, Strang J, Young S, Landau S, Thomson L. Asherson P, et al. Trials. 2019 Dec 2;20(1):663. doi: 10.1186/s13063-019-3705-9. Trials. 2019. PMID: 31791384 Free PMC article. Clinical Trial.
Pharmacoepidemiological studies, a small randomised controlled trial and open trial data of methylphenidate suggest clinically significant reductions in ADHD symptoms, emotional dysregulation, disruptive behaviour and increased engagement with educational activities. ...To …
Pharmacoepidemiological studies, a small randomised controlled trial and open trial data of methylphenidate suggest clinically signif …
Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study.
Matthijssen AM, Dietrich A, Bierens M, Kleine Deters R, van de Loo-Neus GHH, van den Hoofdakker BJ, Buitelaar JK, Hoekstra PJ. Matthijssen AM, et al. Am J Psychiatry. 2019 Sep 1;176(9):754-762. doi: 10.1176/appi.ajp.2019.18111296. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109200 Clinical Trial.
The authors investigated whether methylphenidate remains beneficial after 2 years of use. METHODS: Ninety-four children and adolescents (ages 8-18 years) who had been treated in regular care with methylphenidate for more than 2 years were randomly assigned to double …
The authors investigated whether methylphenidate remains beneficial after 2 years of use. METHODS: Ninety-four children and adolescen …
Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Ramtvedt BE, Aabech HS, Sundet K. Ramtvedt BE, et al. J Child Adolesc Psychopharmacol. 2014 Apr;24(3):130-9. doi: 10.1089/cap.2013.0114. Epub 2014 Mar 25. J Child Adolesc Psychopharmacol. 2014. PMID: 24666268 Free PMC article. Clinical Trial.
Barkley's Side-Effect Rating Scale (SERS), rated by parents, was used to assess adverse events. ...CONCLUSIONS: The availability of both dextroamphetamine and methylphenidate may contribute to minimize adverse events in a subsample of children in pediatric ADHD stim …
Barkley's Side-Effect Rating Scale (SERS), rated by parents, was used to assess adverse events. ...CONCLUSIONS: The availability of b …
Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial.
Dehbozorghi S, Bagheri S, Moradi K, Shokraee K, Mohammadi MR, Akhondzadeh S. Dehbozorghi S, et al. Psychiatry Clin Neurosci. 2019 Nov;73(11):690-696. doi: 10.1111/pcn.12913. Epub 2019 Aug 3. Psychiatry Clin Neurosci. 2019. PMID: 31294924 Free article. Clinical Trial.
AIM: This study evaluated the efficacy and safety of tipepidine as an add-on to methylphenidate in the drug treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS: This study was an 8-week, randomized, parallel group, double-blind, placebo-controlled trial r …
AIM: This study evaluated the efficacy and safety of tipepidine as an add-on to methylphenidate in the drug treatment of attention-de …
Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial.
Konrad K, Günther T, Heinzel-Gutenbrunner M, Herpertz-Dahlmann B. Konrad K, et al. J Child Adolesc Psychopharmacol. 2005 Apr;15(2):180-90. doi: 10.1089/cap.2005.15.180. J Child Adolesc Psychopharmacol. 2005. PMID: 15910203 Clinical Trial.
The aim of this study was to determine drug-dependent effects on attention and motor activity in children with attention-deficit/hyperactivity disorder (ADHD) in a double-blind methylphenidate (MPH) trial using both subjective behavior ratings and objective measures of fun …
The aim of this study was to determine drug-dependent effects on attention and motor activity in children with attention-deficit/hyperactivi …
Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects.
Aman MG, Kern RA, McGhee DE, Arnold LE. Aman MG, et al. J Am Acad Child Adolesc Psychiatry. 1993 Jul;32(4):851-9. doi: 10.1097/00004583-199307000-00022. J Am Acad Child Adolesc Psychiatry. 1993. PMID: 8340309 Clinical Trial.
Teacher ratings indicated significant improvements with both active drugs on subscales designated as Conduct Problem, Hyperactivity, and Irritability, but methylphenidate alone produced improvements on an Inattention subscale. ...Fenfluramine caused significant weight redu …
Teacher ratings indicated significant improvements with both active drugs on subscales designated as Conduct Problem, Hyperactivity, and Irr …
Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial.
Moshe K, Karni A, Tirosh E. Moshe K, et al. Atten Defic Hyperact Disord. 2012 Sep;4(3):153-8. doi: 10.1007/s12402-012-0078-2. Epub 2012 May 24. Atten Defic Hyperact Disord. 2012. PMID: 22622628 Clinical Trial.
To examine the relationship between attention and anxiety and the response to methylphenidate in children with attention deficit hyperactivity disorder (ADHD), a total of 57 boys, between the ages of 7-12 years, were assessed for their attention and level of anxiety. Me …
To examine the relationship between attention and anxiety and the response to methylphenidate in children with attention deficit hype …
A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study).
Hegerl U, Mergl R, Sander C, Dietzel J, Bitter I, Demyttenaere K, Gusmão R, González-Pinto A, Zorrilla I, Alocén AG, Sola VP, Vieta E, Juckel G, Zimmermann US, Bauer M, Sienaert P, Quintão S, Edel MA, Bolyos C, Ayuso-Mateos JL, López-García P, Kluge M. Hegerl U, et al. Eur Neuropsychopharmacol. 2018 Jan;28(1):185-194. doi: 10.1016/j.euroneuro.2017.11.003. Epub 2017 Nov 23. Eur Neuropsychopharmacol. 2018. PMID: 29174864 Clinical Trial.
The MEMAP study - a multi-center, double-blind, placebo-controlled and randomized clinical trial (RCT) - assessed the antimanic efficacy and safety of a 2.5-day treatment with methylphenidate (20-40mg/day). Of 157 screened patients with acute mania, 42 were randomly assign …
The MEMAP study - a multi-center, double-blind, placebo-controlled and randomized clinical trial (RCT) - assessed the antimanic efficacy and …
Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial.
Rafeiy-Torghabeh M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Rafeiy-Torghabeh M, et al. Eur Child Adolesc Psychiatry. 2021 May;30(5):799-807. doi: 10.1007/s00787-020-01562-z. Epub 2020 May 24. Eur Child Adolesc Psychiatry. 2021. PMID: 32449130 Clinical Trial.
This study aimed to evaluate the efficacy and tolerability of resveratrol (that have been shown to have antioxidative, anti-inflammatory, and anti-apoptotic effects) as an adjunct to methylphenidate in pharmacologic treatment of ADHD. This 8-week, double-blinded, placebo-c …
This study aimed to evaluate the efficacy and tolerability of resveratrol (that have been shown to have antioxidative, anti-inflammatory, an …
1,730 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page